Related Experiment Video
Updated: Jun 22, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia
D Masuda1, Y Nakagawa-Toyama, K Nakatani
1Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka, Japan. masuda@imed2.med.osaka-u.ac.jp
European Journal of Clinical Investigation
|June 4, 2009
Summary
Ezetimibe improves fasting lipid profiles and reduces postprandial hyperlipidaemia in type IIb hyperlipidaemia patients by inhibiting intestinal cholesterol absorption. This treatment may help reduce atherosclerosis risk.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Metabolic Disorders
Background:
- Postprandial hyperlipidaemia is a significant risk factor for atherosclerotic disease due to triglyceride-rich lipoprotein accumulation.
- The Niemann-Pick C1-Like 1 (NPC1L1) protein is a key intestinal cholesterol transporter.
- Ezetimibe, an NPC1L1 inhibitor, is used for hypercholesterolaemia.
Purpose of the Study:
- To investigate the effects of ezetimibe on fasting lipid profiles.
- To assess ezetimibe's impact on postprandial hyperlipidaemia in type IIb hyperlipidaemia patients.
Main Methods:
- Ten patients with type IIb hyperlipidaemia received ezetimibe 10 mg/day for 2 months.
- Fasting lipid and lipoprotein profiles were analyzed.
- An oral fat loading (OFL) test was performed to evaluate postprandial responses.
Main Results:
- Ezetimibe significantly reduced fasting levels of total cholesterol, LDL-cholesterol, apoB-100, triglycerides (TG), apoB-48, and remnant lipoprotein cholesterol (RemL-C).
- HPLC analysis indicated decreased cholesterol and TG in VLDL and LDL particles, suggesting reduced VLDL/LDL particle numbers.
- Postprandial analysis showed ezetimibe reduced TG, apoB-48, and RemL-C, and suppressed chylomicron (CM) production and postprandial cholesterol/TG elevations.
Conclusions:
- Ezetimibe improves fasting lipoprotein profiles and postprandial hyperlipidaemia in type IIb hyperlipidaemia.
- The mechanism involves suppression of intestinal chylomicron production.
- Ezetimibe treatment may be effective in reducing atherosclerosis progression.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...